My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

34.34 +3.65 (+11.89%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗

October 20, 2025

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

Via Benzinga

These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond ↗

October 20, 2025

These companies are jockeying for position in a potential $150 billion market opportunity.

Via The Motley Fool

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? ↗

October 17, 2025

These stocks have climbed in the triple digits over the past few years.

Via The Motley Fool

Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts ↗

October 06, 2025

Via Stocktwits

Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly? ↗

October 16, 2025

The smaller drugmaker is looking to disrupt a fast-growing market.

Via The Motley Fool

Down 44%, Should You Buy the Dip on Viking Therapeutics? ↗

October 13, 2025

The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.

Via The Motley Fool

4 Healthcare Stocks to Buy Now ↗

October 12, 2025

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

Via The Motley Fool

Topics Artificial Intelligence

Why Shares in Viking Therapeutics Surged This Week ↗

October 09, 2025

The small-cap pharmaceutical company may be the next in line as takeover fever heats up.

Via The Motley Fool

The Best Stocks to Invest $1,000 in Right Now ↗

October 05, 2025

Buying these three stocks offers you instant diversification.

Via The Motley Fool

Topics Artificial Intelligence

Why This Beaten-Down GLP-1 Stock Could Be a Steal ↗

September 30, 2025

There's more to this company than its performance on the stock market this year suggests.

Via The Motley Fool

Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. ↗

September 25, 2025

Investors once speculated that Pfizer might consider acquiring Viking.

Via The Motley Fool

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ ↗

September 22, 2025

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Via Stocktwits

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

6 Health Care Stocks Whale Activity In Today's Session ↗

September 22, 2025

Via Benzinga

Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months ↗

September 19, 2025

Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.

Via The Motley Fool

Topics Bankruptcy

Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗

September 17, 2025

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

Via MarketBeat

Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook

September 15, 2025

Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback ↗

September 11, 2025

One of them is already a leader in the market for weight management drugs, and the other could join this field.

Via The Motley Fool

Topics ETFs

Peering Into Viking Therapeutics's Recent Short Interest ↗

September 09, 2025

Via Benzinga

Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time. ↗

September 07, 2025

The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.

Via The Motley Fool

Jim Cramer Expects Palantir To Reach New All-Time High ↗

September 05, 2025

Market analysts and financial commentators provide crucial guidance in the volatile investment landscape. Cramer says no to VKTX, but expects PLTR to go up.

Via Benzinga

Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗

September 05, 2025

Viking aims to enter the billion-dollar weight loss drug market.

Via The Motley Fool

Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗

September 04, 2025

Both companies have made significant progress in recent years.

Via The Motley Fool

The Problem With Weight Loss Stocks ↗

September 03, 2025

There are new ways to tackle weight loss, but the stocks leading the way are lagging.

Via The Motley Fool

Topics Economy

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗

August 29, 2025

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

Via The Motley Fool

Why Viking Therapeutics Stock Popped Nearly 4% Today ↗

August 28, 2025

The company's obesity drug could have more potential than originally believed.

Via The Motley Fool

Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk) ↗

August 27, 2025

Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock.

Via The Motley Fool

Topics Economy World Trade

Why Is Viking Therapeutics Stock Crashing, and Is It a Buying Opportunity? ↗

August 27, 2025

The market for weight loss treatments is growing significantly and is forecast to continue increasing for several years.

Via The Motley Fool

Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump ↗

August 26, 2025

Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test.

Via Investor's Business Daily

Viking Therapeutics: What's Next? ↗

August 26, 2025

Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.